NSCLC Liquid Biopsies and Exhaled VOC
A Prospective, Single Center Study to Test the Validity and Feasibility of Circulating Tumor DNA in Blood, Sputum and Alveolar Fluid, as Well as Exhaled Volatile Organic Compounds as Biomarkers in Non-Small Cell Lung Cancer
St. Joseph's Healthcare Hamilton
210 participants
Feb 1, 2023
OBSERVATIONAL
Conditions
Summary
The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for detecting mutations in extracted cell-free DNA in non-small cell lung cancer (NSCLC) patients, before and after surgery, and any recurrence within a 24-month postoperative follow-up period. This is a pilot feasibility study, proposed as a 24-month prospective, single-center, non-interventional, observational trial with NSCLC-adenocarcinoma patients indicated for resection surgery with curative intent.
Eligibility
Inclusion Criteria3
- Patient must be at least 18 years of age
- Patient must be able to provide consent
- Patients undergoing surgical resection with curative intent for non-small cell lung cancer at St. Joseph's Healthcare Hamilton and Firestone Institute for Respiratory Health.
Exclusion Criteria3
- Resection done with non-curative intent or metastatic disease
- other malignancies
- Patients with previously treated malignancy less than 5 years prior to current resection (not including skin cancer).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06707519